Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shenzhen YHLO Biotech CoSHSE:688575 +5.13%64 EV-to-EBIT is 32.99 as of Sep. 21, 2026, which is 4% below its 10-year median of 34.52. GuruFocus rates SHSE:688575 with a GF Score™ of 64/100 and a GF Value™ of ¥15.87 (Significantly Undervalued). The stock has 6 warning signs investors should review. Among 482 Medical Devices & Instruments companies, Shenzhen YHLO Biotech Co ranks worse than 74.48% on this metric.
The historical rank and industry rank for Shenzhen YHLO Biotech Co's EV-to-EBIT or its related term are showing as below:
SHSE:688575'
s EV-to-EBIT Range Over the Past 10 Years
Min: 8.21 Med: 34.52 Max: 94.54
Current: 32.99
During the past 8 years, the highest EV-to-EBIT of Shenzhen YHLO Biotech Co was 94.54. The lowest was 8.21. And the median was 34.52.
SHSE:688575's EV-to-EBIT is ranked worse than 74.48% of 482
companies
in the Medical Devices & Instruments industry
Industry Median: 17.95
vs SHSE:688575: 32.99
Shenzhen YHLO Biotech Co (SHSE:688575) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Shenzhen YHLO Biotech Co's Enterprise Value for the quarter that ended in Jun. 2026 was ¥5,301 Mil.
Shenzhen YHLO Biotech Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥186 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shenzhen YHLO Biotech Co EV-to-EBIT Related Terms
Shenzhen YHLO Biotech Co EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:688575 vs ABT, SYK, MDT: EV-to-EBIT Comparison
For the Medical Devices subindustry, Shenzhen YHLO Biotech Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shenzhen YHLO Biotech Co EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Shenzhen YHLO Biotech Co's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Shenzhen YHLO Biotech Co's EV-to-EBIT falls into.
Shenzhen YHLO Biotech Co's current Enterprise Value is ¥6,123 Mil.
Shenzhen YHLO Biotech Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥186 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shenzhen YHLO Biotech Co (SHSE:688575) has a EV-to-EBIT of 32.99 as of Sep. 21, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Shenzhen YHLO Biotech Co and its competitors. This is near median its historical median of 34.52. Over the past decade, Shenzhen YHLO Biotech Co's EV-to-EBIT has ranged from 8.21 to 94.54. According to the industry distribution chart, Shenzhen YHLO Biotech Co ranks #359 out of 482 companies in the Medical Devices & Instruments industry, placing it in the top 74.5%.
Is Shenzhen YHLO Biotech Co's EV-to-EBIT too high?
Shenzhen YHLO Biotech Co's current EV-to-EBIT of 32.99 is near median its 10-year median of 34.52. Over the past 10 years, this metric has ranged from a low of 8.21 to a high of 94.54. The Medical Devices & Instruments industry median EV-to-EBIT is 17.95. Shenzhen YHLO Biotech Co's value of 32.99 is 83.8% above this industry median. Based on the distribution chart, Shenzhen YHLO Biotech Co ranks #359 out of 482 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Shenzhen YHLO Biotech Co has a GF Score™ of 64/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shenzhen YHLO Biotech Co's EV-to-EBIT compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Shenzhen YHLO Biotech Co ranks #359 out of 482 companies for EV-to-EBIT. This places Shenzhen YHLO Biotech Co in the lower half of its industry. The industry median EV-to-EBIT is 17.95. Shenzhen YHLO Biotech Co's value of 32.99 is 83.8% above this benchmark. Historically, Shenzhen YHLO Biotech Co's own EV-to-EBIT has ranged from 8.21 to 94.54 over the past decade. While the company's 10-year median is 34.52 vs. the industry median of 17.95, Shenzhen YHLO Biotech Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 17.95, based on 482 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shenzhen YHLO Biotech Co's current EV-to-EBIT of 32.99 is 83.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Shenzhen YHLO Biotech Co and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 17.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shenzhen YHLO Biotech Co's current EV-to-EBIT is 32.99, which is near median its own 10-year median of 34.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shenzhen YHLO Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Shenzhen YHLO Biotech Co (SHSE:688575) is currently considered Significantly Undervalued. The stock's GF Value™ is ¥15.87, compared to a current price of ¥10.24 — trading 35.5% below its estimated fair value. The current EV-to-EBIT is 32.99, which is near median its 10-year median of 34.52 and 83.8% above the Medical Devices & Instruments industry median of 17.95. Shenzhen YHLO Biotech Co's overall GF Score™ is 64/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Shenzhen YHLO Biotech Co (SHSE:688575), the current EV-to-EBIT is 32.99 as of Sep. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shenzhen YHLO Biotech Co (SHSE:688575) Overvalued in 2026?
Based on GuruFocus' analysis, Shenzhen YHLO Biotech Co stock appears to be undervalued.
The current stock price of ¥10.24 is trading 35.5% below its estimated GF Value™ of ¥15.87.
GuruFocus considers Shenzhen YHLO Biotech Co to be Significantly Undervalued.
Key valuation signals for SHSE:688575:
EV-to-EBIT: 32.99 (near median its 10-year median of 34.52)
GF Value™: ¥15.87 vs. price of ¥10.24 (35.5% below fair value)
Industry Position: 83.8% above the Medical Devices & Instruments median (#359 of 482)
No single metric tells the full story. See the SHSE:688575 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shenzhen YHLO Biotech Co Ltd is engaged in the research, development, production and sales of in vitro diagnostic instruments and supporting reagents based on chemiluminescence immunoassay. Its product portfolio includes solutions based on technologies such as chemiluminescence, biochemistry, indirect immunofluorescence, immunoblotting, fluorescent immunochromatography, and colloidal gold immunochromatography. Its products are used in diagnostic applications including autoimmunity, reproductive health, infection, liver disease, and respiratory disease testing, and are supplied to healthcare institutions and testing centers.
64GF Score
Get the complete analysis for SHSE:688575
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688575 has been successfully added to your 
